2026-09-21T17:20:56Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/336232022-01-13T07:54:33Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023
Darrell J. Irvine.
Huffman, Kathleen Renee
Massachusetts Institute of Technology. Dept. of Materials Science and Engineering.
Massachusetts Institute of Technology. Department of Materials Science and Engineering
2006-07-31T15:17:56Z
2006-07-31T15:17:56Z
2005
2005
http://hdl.handle.net/1721.1/33623
64391658
Thesis (M. Eng.)--Massachusetts Institute of Technology, Dept. of Materials Science and Engineering, 2005.
Includes bibliographical references (leaves 81-87).
Research into novel vaccine methods is becoming increasingly important for the potential treatment of widespread diseases such as cancer, HIV, and malaria. Members of the Irvine laboratory have developed a hydrogel and particle-based injectable vaccine with the potential to treat such diseases. The vaccine aims to elicit a tailored immune response to a particular type of disease so as to destroy infected or cells in the body and/or develop immunological memory for future protection against the disease. The purpose of this paper is to analyze the feasibility of getting such a biomaterials-based novel vaccination method to the market. Topics such as application potential, efficacy, modes of delivery, storage, patent ability, and costs for producing the vaccine are explored. Finally, a suggested business strategy is outlined, through which value can be successfully obtained from the novel vaccine.
by Kathleen Renee Huffman.
M.Eng.
87 leaves
6229284 bytes
6233211 bytes
application/pdf
application/pdf
eng
Massachusetts Institute of Technology
M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
http://dspace.mit.edu/handle/1721.1/7582
Materials Science and Engineering.
Technical, economic, and clinical challenges to the development of new biomaterials-based vaccines
Thesis
application/pdf
false
Publication
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="4254ffba-5aa8-4d17-9111-92b2b9c52762">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Technical, economic, and clinical challenges to the development of new biomaterials-based vaccines</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2005</PublicationDate>
<Authors>
<Author>
<DisplayName>Huffman, Kathleen Renee</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Materials Science and Engineering.</Keyword>
<Abstract>Research into novel vaccine methods is becoming increasingly important for the potential treatment of widespread diseases such as cancer, HIV, and malaria. Members of the Irvine laboratory have developed a hydrogel and particle-based injectable vaccine with the potential to treat such diseases. The vaccine aims to elicit a tailored immune response to a particular type of disease so as to destroy infected or cells in the body and/or develop immunological memory for future protection against the disease. The purpose of this paper is to analyze the feasibility of getting such a biomaterials-based novel vaccination method to the market. Topics such as application potential, efficacy, modes of delivery, storage, patent ability, and costs for producing the vaccine are explored. Finally, a suggested business strategy is outlined, through which value can be successfully obtained from the novel vaccine.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>